title: Commentary: FGF21 holds promises for treating obesity-related insulin resistance and hepatosteatosis.
authors.affiliation: Liver Research Unit (A.A., N.P.) and Hepato-Metabolic Disease Unit (V.N.), Bambino Gesù Children's Hospital, Instituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy.
authors.forename: Anna
authors.initials: A
authors.lastname: Alisi
authors.forename: Nadia
authors.initials: N
authors.lastname: Panera
authors.forename: Valerio
authors.initials: V
authors.lastname: Nobili
mesh_terms: D005234:Fatty Liver / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D005346:Fibroblast Growth Factors / Q000627:therapeutic use*; D006801:Humans; D007333:Insulin Resistance; D009765:Obesity / Q000150:complications* / Q000378:metabolism
chemical_list: C414620:fibroblast growth factor 21; D005346:Fibroblast Growth Factors